从9例药品不良事件探讨氨溴索联合地塞米松雾化吸入给药的合理性  

Through 9 cases of adverse drug events to explore rationality of atomizing inhalation ambroxol combined with dexamethasone

作　　者：李莉[1] 金海浩[2] 黄清杰[1] 

机构地区：[1]甘肃省中医院药学部,甘肃兰州730050 [2]甘肃省中医院肺病科,甘肃兰州730050

出　　处：《中国新药与临床杂志》2014年第12期919-921,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的探讨注射用氨溴索联合地塞米松注射液雾化吸入的合理性,为临床用药提供参考。方法收集本院肺病科2012年8月至2013年8月使用注射用盐酸氨溴索联合地塞米松磷酸钠注射液雾化吸入导致的药品不良事件(ADE)报道,分析患者性别、年龄,ADE出现时间、类型、处理及转归等。结果共收集注射用氨溴索和地塞米松注射液雾化吸入导致ADE 9例,8例表现为呼吸困难,1例表现为恶心,与使用的药物、给药途径及配伍有关,不除外雾化以及原患疾病因素。结论注射用氨溴索和地塞米松注射液不宜联合雾化吸入给药,建议临床选择雾化吸入专用剂型。AIM To explore the rationality of atomizing inhalation ambroxol for injection combined with dexamethasone injection for references of rational drug use in clinic. METHODS The adverse drug events （ADE） reports caused by the combination atomization inhalation of ambroxol hydrochloride for injection and dexamethasone sodium phosphate injection which occurred in the department of pulmonology of our hospital from August 2012 to August 2013 were collected. The content including patients＇ sex and age, occurrence time and types of ADE, and clinical manifestation etc. were analyzed. RESULTS A total of 9 ADE cases were collected which caused by the ambroxol for injection and dexamethasone injection combination of atomization inhalation. The main presentation of the ADE was dyspnea, occurred in 8 patients. And nausea occurred in 1 patient. The ADE was related to the use of drugs, the route of administration, drugs compatibility, but atomization and primary disease factors cannot be excluded. CONCLUSION It is unreasonable of atomizing inhalation ambroxol for injection combined with dexamethasone injection. The special form for inhalation should be recommended in clinic.

关 键 词：氨溴索 地塞米松 投药 吸入 药品不良事件 雾化吸入 

分 类 号：R974[医药卫生—药品]